Clinical Trials for Kidney Cancer
The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost.
The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients. The KCRC includes some of the highest volume renal cell carcinoma clinical trial sites in the country.
Open Trials
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Ipilimumab, Nivolumab, and Ciforadenant as First-Line Therapy for Stage IV Renal Cell Carcinoma
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Carcinoma
Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Ipilimumab, Nivolumab, and Ciforadenant as First-Line Therapy for Stage IV Renal Cell Carcinoma
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Carcinoma (FORTUNE)
Upcoming Trials
Phase II study of evolocumab and nivolumab in patients with metastatic renal cell carcinoma refractory to PD-1 and VEGF blockade
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in renal cell carcinoma patients with brain metastasis previously treated with immune checkpoint blockade
Phase II study of evolocumab and nivolumab in patients with metastatic renal cell carcinoma refractory to PD-1 and VEGF blockade
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in renal cell carcinoma patients with brain metastasis previously treated with immune checkpoint blockade
Information for Patients
Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.
Research News
Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.
The Kidney Cancer Research Consortium Members
The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.
Eric Jonasch, M.D.
Dr. Jonasch leads the Consortium. He is a professor in the Department of GU Medical Oncology, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center. Dr. Jonasch's research focuses on clear-cell RCC and VHL with an interest in replication stress and microenvironmental determinants of resistance to therapy.
Hans Hammers, M.D., Ph.D.
Dr. Hammers is a nationally and internationally recognized medical oncologist focusing primarily on kidney cancer. Dr. Hammers is an international thought leader in immunotherapy, a form of treatment that boosts the body’s own immune defenses to help fight cancer – and one that is changing the kidney cancer landscape.
Brian Rini, M.D.
Dr. Rini is an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development. He is an Ingram Professor of Medicine at Vanderbilt University in the deperatments of hematology and oncology, where he leads kidney cancer clinical research efforts, and also serves as the Chief of Clinical Trials.
Naomi Haas, M.D.
Dr. Haas is an international expert in the conduct and design of adjuvant clinical trials for kidney cancer, as well as a national expert in prostate and kidney cancer therapeutics. She is the director of the Prostate and Kidney Cancer Program at UPenn, as well as co-leader of the Cancer Therapeutics Program at Abramson Cancer Center.
Daniel George, M.D.
Dr. George oversees a large clinical research team at Duke focused on developing therapy and improving care and outcomes for patients with urologic cancers. His work involves both interventional trials with new and emerging therapies, as well as diagnostic tests and markers of cancer biology, response, and outcome.
David McDermott, M.D.
Dr. McDermott is a professor of medicine at Harvard, as well as the co-leader of the Kidney Cancer program at Dana-Farber/HCC. He focuses on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology, and novel therapeutic targets for various kidney cancer populations.
Ulka Vaishampayan, M.D., Ph.D.
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies.
The Latest Tweets from Consortium Investigators:
; This thread! Catching up on tweets on a slow Thanksgiving morning. So grateful to have Dr. @KimrynRathmell at the helm of @theNCI.
Today, we're grateful for our incredible community. To the researchers, healthcare professionals, advocates, patients, families, and friends: you are the driving force behind our mission to accelerate cures for kidney cancer.
Wishing you all a joyful Thanksgiving. 🧡
👨⚕️ Dr. @HHammersMD outlines rationale for targeting PTPN2 in RCC—anticipating dual impact on cancer cells and immunomodulation. Excitement builds for upcoming clinical trial results with RCC cohort and KCRC involvement! 🚀🔍 #RCCResearch #KCRC
@HHammersMD driving the immunomodulatory story for #kidneycancer — new trial opening thru @utswcancer DOD kidney cancer clinical trials research consortium! @KidneyCancer @kidneycan @kcCURE
What a win for all of us! 🤩
@KimrynRathmell, renowned #kidneycancer expert and frequent speaker at #KCRS, has been appointed by @POTUS as the new Director of @theNCI.
Congratulations, Dr. Rathmell! 🌟
#KidneyCancerResearch #NCI #CancerMoonshot #AcceleratingCures @OncoAlert
Wonderful news! Congrats @KimrynRathmell @VUMCHemOnc @POTUS
All Uromigos Live 2023 videos are now on our YouTube page:
Enjoy!!
Did you know? We are already gearing up for #KCRS24, and you can pre-register now!
➡️
In the meantime, let's revisit the exciting Trials in Progress session from #KCRS23 with Dr. Naomi Haas of UPenn:
https://youtu.be/UBTwbJFCqSY
While at #UromigosLive, @katy_beckermann shared how she enjoyed the discussion on #belzutifan for patients with #kidneycancer, and explained the need to identify a biomarker for patients who will benefit from this drug. Watch now: https://buff.ly/3u8Q3bd
